News
Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
Conference call begins at 8:30 a.m. Eastern time todayWOBURN, MA / ACCESSWIRE / August 11, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial...
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Basal Cell Carcinoma
Trial Results Expected in Mid-2024WOBURN, MA / ACCESSWIRE / August 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces that patient enrollment is now...
Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023
WOBURN, MA / ACCESSWIRE / August 4, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2023 before...
Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%
Management Reaffirms Full-Year 2023 Revenue Growth of at least 25% over Prior YearWOBURN, MA / ACCESSWIRE / July 13, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of...
Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors
WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of...
Biofrontera Inc. Announces 1-for-20 Reverse Stock Split
WOBURN, MA / ACCESSWIRE / July 3, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that it will effect a reverse stock split of its outstanding...
Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.
WOBURN, MA / ACCESSWIRE / June 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces its sponsorship of The Sun Bus, a mobile classroom and...
Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz®-PDT
WOBURN, MA / ACCESSWIRE / June 1, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces it has engaged a contract manufacturer to develop a new,...
Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer
WOBURN, MA / ACCESSWIRE / May 30, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that its Board of Directors has named Hermann Luebbert as...
Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects
Novel Protocol is Expected to be Less Painful with Efficacy Similar to Conventional PDTWOBURN, MA / ACCESSWIRE / May 15, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products,...